News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
ERYtech Pharma Enrolled Its Last Patient for Its Phase II GRASPALL Clinical Trial and Selects Philadelphia Science Center as US Headquarters
June 12, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LYON,France & PHILADELPHIA, Pa.--(BUSINESS WIRE)--ERYtech Pharma announces the inclusion of its last patient in its Phase II clinical trial for relapsed Acute Lymphoblastic Leukaemia (ALL).
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Europe
MORE ON THIS TOPIC
Phase 3
Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition
August 13, 2026
·
3 min read
·
Gabrielle Masson
Insights
The Italian inflection point: Clinical strength, culture and capital
August 13, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Rare diseases
Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug
August 12, 2026
·
3 min read
·
Annalee Armstrong
IPO
2026 IPO stock tracker: How newly public biotechs are performing
August 12, 2026
·
1 min read
·
Gabrielle Masson
